SVCM
SLN

Saturn V Capital Management’s Silence Therapeutics SLN Stock Holding History

Saturn V Capital Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-34,737
Closed -$201K – 24
2025
Q2 		$201K Sell
34,737
-697,726
-95% -$2.99M 0.08% 24
2025
Q1 		$2.07M Buy
732,463
+337,439
+85% +$1.65M 1.04% 19
2024
Q4 		$2.72M Sell
395,024
-86,103
-18% -$1.11M 1.06% 21
2024
Q3 		$8.75M Buy
+481,127
New +$8.95M 3.13% 13

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Saturn V Capital Management's SLN Position: Q3 2025 in Review

Saturn V Capital Management sold out of Silence Therapeutics (SLN) in Q3 2025, closing a stake of 34,737 shares — an estimated $201K sold.

Saturn V Capital Management first reported a position in SLN in Q3 2024 and held it in 4 quarters. The position peaked at $8.75M in Q3 2024. 54 funds tracked by Wall St. Rank hold SLN as of Q3 2025.

  • Saturn V Capital Management reported no remaining Silence Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Saturn V Capital Management sold 34,737 Silence Therapeutics shares in Q3 2025, an estimated $201K.
  • Saturn V Capital Management first reported a position in Silence Therapeutics in Q3 2024 and held it in 4 quarters.
  • Saturn V Capital Management's Silence Therapeutics position peaked at $8.75M in Q3 2024.
  • 54 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2025.

Based on Saturn V Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.